Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2002

View Archived Issues

Pilot study of the humanized anti-C5 monoclonal antibody eculizumab in dermatomyositis

Better gastrointestinal tolerability for AZD-3582 compared to naproxen in man

Novel melanocortin MC4 receptor agonists under study at Merck

Meiji Seika presents new macrolide antibiotics for Gram-positive bacterial infections

Orally available prodrugs of SGLT-2 inhibitors covered by Kissei patent

New PAR-1 antagonists prepared and tested at Ortho-McNeil

NIH researchers identify novel thalidomide analogues

PDE2 inhibitors and their use in cognition disorders

Mitsubishi Pharma claims new tyrosine kinase inhibitors for cancer and other proliferative disorders

Sanguine to enter agreement with City of Hope for PHER-02

FDA accepts Oxytrol NDA for filing

Phase III oritavancin trial completes enrollment

Cytovaxine phase I trial completes enrollment

Norak licenses Transfluor technology to Roche for GPCR drug discovery

Positive phase I results for GH-9001

A-278637: enhanced bladder selectivity and potency as compared to other KCOs

FDA approves first-in-class cholesterol-lowering agent

TMI-1: a dual TACE/MMP inhibitor identified using structure-based design

Once-weekly dosing of dalbavancin appears feasible

Favorable PK and drug interaction data reported for anidulafungin at IDSA

Sustained activity demonstrated for Albugranin in two animal species

Fluoroquinolone ABT-492 shows particularly promising activity against respiratory pathogens

ABI-001 production set to begin

Metabolic Pharmaceuticals offers progress report

Positive phase III results for MethyPatch in ADHD

Approvable letter for rifaximin in travelers' diarrhea

Jerini initiates phase I trial of icatibant for decompensated liver cirrhosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...